MG
EW icon

Michael Gelband’s Edwards Lifesciences EW Stock Holding History

Michael Gelband’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,100
Closed -$168K – 2071
2020
Q3 		$168K Buy
+2,100
New +$164K ﹤0.01% 1521

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Michael Gelband's EW Position: Q2 2026 in Review

Michael Gelband reduced its Edwards Lifesciences (EW) stake by 86% in Q2 2026, selling an estimated $15.4M and leaving 31,025 shares worth $2.81M. The position accounts for 0.02% of the portfolio, ranked #687.

Michael Gelband first reported a position in EW in Q4 2018 and has held it in 19 quarters since. The position peaked at $24.2M in Q4 2025. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Michael Gelband held 31,025 shares of Edwards Lifesciences worth $2.81M as of Q2 2026.
  • Michael Gelband sold 184,099 Edwards Lifesciences shares in Q2 2026, an estimated $15.4M.
  • Edwards Lifesciences made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #687 holding.
  • Michael Gelband first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 19 quarters since.
  • Michael Gelband's Edwards Lifesciences position peaked at $24.2M in Q4 2025.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.